Literature DB >> 25125565

HIV-1 clinical isolates with the E138A substitution in reverse transcriptase show full susceptibility to emtricitabine and other nucleoside reverse transcriptase inhibitors.

Danielle P Porter1, Rima Kulkarni2, Kirsten L White2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25125565      PMCID： PMC4135858          DOI： 10.1128/AAC.03173-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Authors:  Laurence Rimsky; Johan Vingerhoets; Veerle Van Eygen; Joseph Eron; Bonaventura Clotet; Annemie Hoogstoel; Katia Boven; Gaston Picchio
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

2.  Update of the drug resistance mutations in HIV-1: March 2013.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Gunthard; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2013 Feb-Mar

3.  Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.

Authors:  Nicolas Sluis-Cremer; Kelly D Huber; Chanson J Brumme; P Richard Harrigan
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

4.  Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Authors:  Hong-Tao Xu; Eugene L Asahchop; Maureen Oliveira; Peter K Quashie; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Authors:  Rima Kulkarni; Kerim Babaoglu; Eric B Lansdon; Laurence Rimsky; Veerle Van Eygen; Gaston Picchio; Evguenia Svarovskaia; Michael D Miller; Kirsten L White
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

6.  Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

Authors:  Danielle P Porter; Rima Kulkarni; Todd Fralich; Michael D Miller; Kirsten L White
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

7.  96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.

Authors:  Laurence Rimsky; Veerle Van Eygen; Annemie Hoogstoel; Marita Stevens; Katia Boven; Gaston Picchio; Johan Vingerhoets
Journal:  Antivir Ther       Date:  2013-05-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.